# Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma

> **NCT05290194** · PHASE2 · RECRUITING · sponsor: **Fifth Affiliated Hospital, Sun Yat-Sen University** · enrollment: 28 (estimated)

## Conditions studied

- Radiotherapy
- PD-1 Inhibitor
- Capecitabine
- Nasopharyngeal Carcinoma

## Interventions

- **RADIATION:** SBRT radiotherapy + Conventionally fractionated radiotherapy
- **DRUG:** PD-1 inhibitor
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT05290194
- **Lead sponsor:** Fifth Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-28
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-01-01
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2022-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05290194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05290194, "Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05290194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*